Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARGX-121 · 1 trial · 1 indication
UPCR is urine protein-to-creatinine ratio
| Arm | Type | Description |
|---|---|---|
| ARGX-121 | EXPERIMENTAL | Participants will receive ARGX-121 in subcutaneous injections during the double blinded treatment period and active only treatment periods (Total of 52 weeks) |
| Placebo followed by ARGX-121 | PLACEBO_COMPARATOR | Participants receive placebo for the double-blinded period of 24 weeks, followed by subcutaneous injections of ARGX-121 during the active only treatment period of 28 weeks. |
| Name | Type | Description |
|---|---|---|
| ARGX-121 | BIOLOGICAL | Subcutaneous Injection of ARGX-121 |
| Placebo | BIOLOGICAL | Subcutaneous Injection of Placebo |
Inclusion Criteria: * Males and females (not pregnant) * At least 18 years old * Clinically diagnosed with IgAN with biopsy confirmation Exclusion Criteria: * Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of Ig...
ARGX-121 is an investigational monoclonal antibody being developed for the treatment of Immunoglobulin A Nephropathy (IgAN), a kidney disease. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ARGX-121 targets IgA, a protein involved in the immune system. By binding to IgA, the drug is designed to interfere with the disease process in Immunoglobulin A Nephropathy (IgAN), potentially reducing proteinuria in affected patients.
ARGX-121 is being developed by argenx SE, a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARGX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with Immunoglobulin A Nephropathy.
ARGX-121 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials for the treatment of Immunoglobulin A Nephropathy.
ARGX-121 is being evaluated in a Phase 2 clinical trial with the identifier NCT07773727. This randomized, double-blind, placebo-controlled study is designed to assess the effect of ARGX-121 on the change in proteinuria in adult participants with Immunoglobulin A Nephropathy, with an estimated enrollment of 120 participants.